Finasteride Dosing for BPH vs Androgenic Alopecia
For benign prostatic hyperplasia (BPH), use finasteride 5 mg once daily; for androgenic alopecia (male pattern hair loss), use finasteride 1 mg once daily. These are the FDA-approved doses with established efficacy for their respective indications 1.
Benign Prostatic Hyperplasia (BPH)
Finasteride 5 mg daily is the standard dose for treating symptomatic BPH in men with documented prostatic enlargement 2, 1. This dose:
- Reduces prostate volume by 15-25% at 6 months 3
- Improves AUA Symptom Index by approximately 3 points (clinically meaningful) 2
- Reduces serum PSA by approximately 50% 2, 3
- Reduces DHT levels in prostate tissue by approximately 80% 3
- Decreases risk of acute urinary retention and need for BPH-related surgery 2
Critical Requirements for BPH Treatment
Finasteride is only appropriate for men with demonstrable prostatic enlargement - specifically prostate volume >30cc or PSA >1.5 ng/mL 2, 3. The drug is ineffective and should not be used in men with LUTS who lack prostatic enlargement 2.
Important Caveats
- Onset of action is slow compared to alpha-blockers; counsel patients on delayed symptom improvement 3
- Less effective than alpha-blockers for immediate symptom relief, but superior for preventing disease progression 2
- Maximum benefit occurs after 6-12 months of continuous therapy
- When screening for prostate cancer, double the measured PSA value after 1 year of therapy to accurately assess disease progression 3
Combination Therapy
Finasteride 5 mg can be combined with alpha-blockers (particularly doxazosin) for men with enlarged prostates and moderate-to-severe symptoms 2. Combination therapy reduces long-term risk of acute urinary retention by 79% and BPH-related surgery more effectively than either agent alone 2.
Androgenic Alopecia (Male Pattern Hair Loss)
Finasteride 1 mg once daily is the FDA-approved dose for male androgenic alopecia 4. This lower dose:
- Reduces serum DHT by approximately 70% (versus 95% with 5 mg) 3
- Reduces serum PSA by 40-50% within 48 weeks 5
- Demonstrates efficacy in stopping hair loss in 85% of men aged 20-40 years 6
- Has established long-term safety data up to 5 years 4
PSA Screening Consideration
Men taking finasteride 1 mg for hair loss should also have their PSA values doubled when screening for prostate cancer, as this dose produces clinically significant PSA suppression comparable to the 5 mg dose 5.
Sexual Adverse Effects (Both Doses)
Sexual dysfunction occurs with both doses but is generally reversible and uncommon after the first year:
- Decreased libido: 6.4% (year 1), 2.6% (years 2-4) 2
- Erectile dysfunction: 8.1% (year 1), 5.1% (years 2-4) 2
- Ejaculatory dysfunction: 3.7% (year 1), 1.5% (years 2-4) 2
These rates are from the 5 mg dose studies; the 1 mg dose appears to have similar or slightly lower rates 7.
Common Pitfall to Avoid
Do not use finasteride 5 mg for hair loss or finasteride 1 mg for BPH. The 1 mg dose lacks clinical trial evidence for BPH outcomes (prostate volume reduction, symptom improvement, progression prevention), though it produces measurable biologic effects on DHT and PSA 8. The 5 mg dose is unnecessarily high for androgenic alopecia and was optimized at 1 mg for this indication 4.